Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Galapagos  /  Galapagos februari 2020

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel Galapagos AEX:GLPG.NL, BE0003818359

  • 26,760 25 apr 2024 15:42
  • -0,360 (-1,33%) Dagrange 26,720 - 26,980
  • 41.585 Gem. (3M) 80,8K

Galapagos februari 2020

6.129 Posts
Pagina: «« 1 ... 228 229 230 231 232 ... 307 »» | Laatste | Omlaag ↓
  2. kwekkel 27 februari 2020 07:53
    quote:

    Föhn schreef op 27 februari 2020 07:34:

    Futs zijn weer vuurrood zeg. Idd fasten your seatbelts
    Dat is niet het enige

    seekingalpha.com/article/4327505-gala...

    Galapagos Receives Rating Downgrade, Stock Skids
    Galapagos NV (GLPG) stock was hit hard as Bank of America downgraded its rating to Sell. The latest downgrade comes after a couple of other such negative recommendations made by other stock research firms. The pharma company stock was recently downgraded by JPMorgan Chase & Co. which pulled its rating from Overweight to Neutral. Similarly, Credit Suisse Group lowered the rating from Outperform to Neutral and slashed the price target from $174 to $169. However, there was a silver lining as well as Stifel increased the price target for the stock to $298, up from $188 price target it had set earlier.
    Galapagos seems to be going through critical times. The company recently reported its financial numbers and provided corporate updates. It reported signing a novel research and development agreement with Gilead Sciences and filed applications for approval of selective JAK1 inhibitor filgotinib in rheumatoid arthritis (NYSE:RA) in the U.S., Europe and Japan by Gilead. The company has received priority review tag for its application in the United States. It also reported starting First in Human Phase 1 trials with TOLEDO compounds GLPG3312 and GLPG3970.
    For its FY2019, the company reported its group revenues & other income at €896 million, compared to €318 million in 2018. The company’s net profit stood at €150 million, compared to a net loss of €29 million in 2018. Ignoring the impact of Gilead transaction, Galapagos’ operational cash burn was reported at €334 million, meeting the guidance. Onno van de Stolpe, CEO of Galapagos said, “At the same time, our pipeline made significant progress in 2019. For the first time in our history, with filgotinib in RA, we have a product candidate under regulatory review for approval in the U.S., Europe, and Japan. Pending potential approval, we are rapidly gearing up to commercialize filgotinib in RA in Europe, hand in hand with our collaboration partner Gilead.”

    Galapagos also provided guidance for FY2020. The company provided details about Phase 3 ISABELA program, for which it is currently recruiting candidates. The company has already enrolled over 600 patients in 2019 while it expects the futility analysis will likely be concluded in the first quarter of 2021. During 2020, the company expects to conduct over 80 clinical trials. Due to heightened research and development activities, the company reckons that its operational cash burn will remain between €420 and €450 million, including milestone income from Gilead for potential regulatory approvals of filgotinib in RA. Galapagos expects the official FY2019 results to be out by March 27, 2020.

    Galapagos stock has shown strong performance in the market. In the past 12 months, it has gained over 130 percent growth. With its new developments, it is expected that the stock will retain its positive trajectory.
  6. [verwijderd] 27 februari 2020 08:19
    Juist, vooral de laatste alinea is geheel niet negatief:

    “Galapagos stock has shown strong performance in the market. In the past 12 months, it has gained over 130 percent growth. With its new developments, it is expected that the stock will retain its positive trajectory.”

    Maar goed, eerst maar eens afwachten wat er de komende weken gebeurt.... kan best nog wel even billenknijpen worden....
6.129 Posts
Pagina: «« 1 ... 228 229 230 231 232 ... 307 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium

Weinig houvast voor beleggers in Galapagos

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Galapagos Nieuws

  1. 12 apr KBC Securities verlaagt koersdoel Galapagos naar 50 euro
  2. 05 apr Galapagos toont innovatieve aanpak in hematologische kankerzorg
  3. 23 feb AEX op de waakvlam het weekend in, koersdreun Besi, Alfen en Galapagos 2
  4. 23 feb Beursblik: gebrek aan opwaarts potentieel voor Galapagos op korte termijn
  5. 23 feb Gaat AEX op recordjacht of gaat de beursweek uit als een nachtkaars?
  6. 23 feb Update : Galapagos voldoet aan verwachtingen
  7. 19 feb Beursblik: cashburn belangrijk voor Galapagos
  8. 15 feb Galapagos presenteert nieuwe onderzoeksdata op EBMT-EHA bijeenkomst
  9. 01 feb Galapagos rondt Jyseleca-transactie af
  10. 04 jan Galapagos in zee met Thermo Fisher

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!